Internal request
Comment to consider the inclusion of sirolimus (for transplant KS) as a single-agent option for subsequent systemic therapy for relapsed/refractory disease.

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>KS-D</td>
<td>Based on the discussion and data in the noted references, the panel consensus was to include sirolimus (for transplant KS) as a single-agent option for subsequent systemic therapy for relapsed/refractory disease. This is a category 2A, useful in certain circumstances recommendation.</td>
<td>YES: 22 / NO: 0 / ABSTAIN: 0 / ABSENT: 8</td>
</tr>
</tbody>
</table>